Loading...

Gregory Daniels

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.

    Education and Training
    BA - Biochemistry & Cellular Biology, University California, San Diego - 1982-1987
    MS - Biochemistry, University of California, San Diego - 1987-1988
    PhD - Cancer Biology, Stanford University - 1989-1997
    MD - USC School of Medicine - 1995-1999
    Resident - Mayo Clinic, Rochester MN - 1999-2002
    Fellowship - Medical Oncology, Mayo Clinic, Rochester, MN - 2002-2005

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget. 2020 Jul 14; 11(28):2740-2746. Yun K, Daniels G, Gold K, Mccowen K, Patel SP. PMID: 32733645.
      View in: PubMed   Mentions:    Fields:    
    2. Author Correction: Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2020 03; 38(3):374. Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC, Schroth GP, Sandberg R. PMID: 32015550.
      View in: PubMed   Mentions:    Fields:    
    3. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw. 2020 02; 18(2):120-131. Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson Iii WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. PMID: 32023525.
      View in: PubMed   Mentions:    Fields:    
    4. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 Jun 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524.
      View in: PubMed   Mentions: 1     Fields:    
    5. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. PMID: 31952975.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    6. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. PMID: 31562797.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    7. Challenge of immune-mediated adverse reactions in the emergency department. Emerg Med J. 2019 Jun; 36(6):369-377. Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J. PMID: 31113799.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 04 01; 17(4):367-402. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. PMID: 30959471.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    10. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49. Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF. PMID: 30777131.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    11. Adjuvant and Neoadjuvant Treatment of Skin Cancer. Facial Plast Surg Clin North Am. 2019 Feb; 27(1):139-150. Sacco AG, Daniels GA. PMID: 30420067.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. J Immunother Cancer. 2018 12 22; 6(1):153. Chang VA, Simpson DR, Daniels GA, Piccioni DE. PMID: 30577851.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions:
    14. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 10; 8(10):1250-1257. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. PMID: 30154193.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    15. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 06; 16(6):742-774. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM. PMID: 29891526.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    16. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 10; 23(10):1236-1241. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. PMID: 29769383.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review. BMC Cancer. 2018 May 09; 18(1):549. McDonald MA, Sanghvi P, Bykowski J, Daniels GA. PMID: 29743050.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405.
      View in: PubMed   Mentions:
    19. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017 12 19; 5(1):102. Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP. PMID: 29254506.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    20. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 03 15; 124(6):1288-1296. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. PMID: 29211306.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    21. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. PMID: 29076950.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    23. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD. PMID: 28915085.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    24. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions:
    25. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5696-5702. Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA. PMID: 28679776.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    26. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017 03; 29(2):129-135. Ribero S, Stucci LS, Daniels GA, Borradori L. PMID: 28151757.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    27. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer. 2017 02; 15(1):31-41.e4. Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. PMID: 27916626.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016 Dec; 175(6):1382-1386. Borradori L, Sutton B, Shayesteh P, Daniels GA. PMID: 27059424.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    29. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544. Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. PMID: 27714434.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    30. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52. Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. PMID: 27660706.
      View in: PubMed   Mentions: 8     Fields:    
    31. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. PMID: 27496110.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    32. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 05; 14(5):574-97. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. PMID: 27160235.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    33. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. PMID: 27059193.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    34. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. . 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions:
    35. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 01; 33(25):2780-8. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. PMID: 26014293.
      View in: PubMed   Mentions: 515     Fields:    Translation:HumansCellsCTClinical Trials
    37. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. . 2015; 14(13):2121-8. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. PMID: 25950492.
      View in: PubMed   Mentions:
    38. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. . 2015 Jun; 14(6):1488-94. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25852059.
      View in: PubMed   Mentions:
    39. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25596748.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    40. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. . 2015; 14(11):1730-7. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25928476.
      View in: PubMed   Mentions:
    41. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. . 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927.
      View in: PubMed   Mentions:
    42. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer. 2014; 2:20. Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. PMID: 25031835.
      View in: PubMed   Mentions: 3     Fields:    
    43. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):863-8. Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, McMillian N, Hoffman K, Ho M. PMID: 24925197.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    44. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. PMID: 24797821.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    45. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M. PMID: 24812131.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    46. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    47. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J Pers Med. 2014 Mar 07; 4(1):52-64. Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. PMID: 25562142.
      View in: PubMed   Mentions:
    48. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):410-24. Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, Hoffmann KG, McMillian NR, Ho M. PMID: 24616545.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    49. Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. Mol Immunol. 2014 Feb; 57(2):191-9. Saenz R, Messmer B, Futalan D, Tor Y, Larsson M, Daniels G, Esener S, Messmer D. PMID: 24172222.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    50. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2012 Aug; 30(8):777-82. Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC, Schroth GP, Sandberg R. PMID: 22820318.
      View in: PubMed   Mentions: 429     Fields:    Translation:HumansAnimalsCells
    51. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):547-52. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. PMID: 21516509.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    52. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res. 2011 Feb; 21(1):66-75. Hayashi T, Chan M, Norton JT, Wu CC, Yao S, Cottam HB, Tawatao RI, Corr M, Carson DA, Daniels GA. PMID: 21030882.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    53. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol. 2006 Sep 15; 177(6):4168-77. Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, Melcher A, Vile RG. PMID: 16951382.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    54. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol. 2004 Sep; 22(9):1125-32. Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. PMID: 15300260.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCellsPHPublic Health
    55. Insertion of the mannitol permease into the membrane of Escherichia coli. Possible involvement of an N-terminal amphiphilic sequence. J Biol Chem. 1991 Sep 25; 266(27):17863-71. Yamada Y, Chang YY, Daniels GA, Wu LF, Tomich JM, Yamada M, Saier MH. PMID: 1917927.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells
    56. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Membr Biol. 1988 Aug; 104(1):1-20. Saier MH, Daniels GA, Boerner P, Lin J. PMID: 3054116.
      View in: PubMed   Mentions: 26     Fields:    Translation:Animals
    57. Properties of a Tn5 insertion mutant defective in the structural gene (fruA) of the fructose-specific phosphotransferase system of Rhodobacter capsulatus and cloning of the fru regulon. J Bacteriol. 1988 Apr; 170(4):1698-703. Daniels GA, Drews G, Saier MH. PMID: 2832374.
      View in: PubMed   Mentions: 9     Fields:    Translation:Cells
    Gregory's Networks
    Concepts (261)
    Derived automatically from this person's publications.
    _
    Co-Authors (50)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _